Sandra Rome, RN

Leukemias and lymphomas are estimated to contribute up to 7% of all new malignant cases in the United States.[1]

The availability of a wide variety of treatments for multiple myeloma allows healthcare providers to tailor treatments to individual patient needs, and has enabled prolonged survival of patients with the disease.